文献速递临床试验与 GCP

替尔泊肽用于中国肥胖成人减重:SURMOUNT-CN随机临床试验

Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

这项在中国29个中心开展的随机、双盲、安慰剂对照3期临床试验纳入210例中国肥胖或超重合并体重相关合并症的成人(排除糖尿病),随机接受每周一次皮下替尔泊肽10 mg、15 mg或安慰剂联合生活方式干预52周。第52周体重平均变化:替尔泊肽10 mg组-13.6%,15 mg组-17.5%,安慰剂组-2.3%,组间差异均具统计学显著性;最常见治疗中出现的不良事件为胃肠道反应,多为轻至中度。

要点

  • 替尔泊肽10 mg和15 mg组第52周体重平均降幅分别为13.6%和17.5%,安慰剂组为2.3%。
  • 体重下降≥5%的受试者比例:10 mg组87.7%、15 mg组85.8%、安慰剂组29.3%。
  • 替尔泊肽最常见治疗中出现的不良事件为胃肠道反应,多为轻至中度。

核心结论

  • 在中国肥胖或超重成人中,每周一次替尔泊肽10 mg或15 mg治疗52周可带来统计学显著且有临床意义的体重下降,安全性可接受。

研究设计与样本

  • 随机、双盲、安慰剂对照3期临床试验,在中国29个中心于2021年9月至2022年12月开展。
  • 纳入年龄≥18岁、BMI≥28或BMI≥24且至少1种体重相关合并症的中国成人,排除糖尿病。
  • 共210例随机分配(1:1:1)接受每周一次皮下替尔泊肽10 mg(n=70)、15 mg(n=71)或安慰剂(n=69),联合生活方式干预,疗程52周。
  • 疗效和安全性分析基于意向性治疗人群。

主要发现

  • 210例随机受试者中103例(49.0%)为女性,平均(SD)年龄36.1(9.1)岁,体重91.8(16.0)kg,BMI 32.3(3.8);201例(95.7%)完成试验。
  • 第52周体重平均变化:替尔泊肽10 mg组-13.6%(95%CI,-15.8%至-11.4%),替尔泊肽15 mg组-17.5%(95%CI,-19.7%至-15.3%),安慰剂组-2.3%。
  • 与安慰剂相比的差异:10 mg组-11.3%(95%CI,-14.3%至-8.3%;P<.001),15 mg组-15.1%(95%CI,-18.2%至-12.1%;P<.001)。
  • 体重下降≥5%的受试者比例:替尔泊肽10 mg组87.7%,替尔泊肽15 mg组85.8%,安慰剂组29.3%(与安慰剂比较P<.001)。
  • 替尔泊肽最常见治疗中出现的不良事件为胃肠道反应,大多为轻至中度,导致治疗中止的事件较少(<5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Obesity has become a global public health concern and China has the largest number of affected people worldwide. OBJECTIVE: To assess the efficacy and safety of treatment with tirzepatide for weight reduction in Chinese adults with obesity or overweight and weight-related comorbidities. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 29 centers in China from September 2021 to December 2022 included Chinese adults (aged ≥18 years) with a body mass index (BMI) greater than or equal to 28 or greater than or equal to 24 and at least 1 weight-related comorbidity, excluding diabetes. INTERVENTIONS: Participants were randomly assigned (1:1:1) to receive once-weekly, subcutaneous 10-mg (n = 70) or 15-mg (n = 71) tirzepatide or placebo (n = 69), plus a lifestyle intervention, for 52 weeks. MAIN OUTCOMES AND MEASURES: Co-primary end points were the percent change in body weight from baseline and weight reduction of at least 5% at week 52. Efficacy and safety analyses were performed on an intention-to-treat population. RESULTS: Of 210 randomized participants (103 [49.0%] female; mean [SD] age, 36.1 [9.1] years; body weight, 91.8 [16.0] kg; BMI, 32.3 [3.8]), 201 (95.7%) completed the trial. The mean change in body weight at week 52 was -13.6% (95% CI, -15.8% to -11.4%) with tirzepatide 10 mg, -17.5% (95% CI, -19.7% to -15.3%) with tirzepatide 15 mg, and -2.3% with placebo (difference between 10 mg and placebo, -11.3% [95% CI, -14.3% to -8.3%; P < .001]; difference between 15 mg and placebo, -15.1% [95% CI, -18.2% to -12.1%; P < .001]). The percentage of participants achieving body weight reductions of 5% or greater was 87.7% with tirzepatide 10 mg, 85.8% with tirzepatide 15 mg, and 29.3% with placebo (P < .001 for comparisons with placebo). The most frequent treatment-emergent adverse events with tirzepatide were gastrointestinal. Most were mild to moderate in severity, with few events leading to treatment discontinuation (<5%). CONCLUSIONS AND RELEVANCE: In Chinese adults with obesity or overweight, once-weekly treatment with tirzepatide 10 mg or 15 mg resulted in statistically significant and clinically meaningful weight reduction with an acceptable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05024032.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. PMID: 38819983. doi:10.1001/jama.2024.9217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。